Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion announced new preclinical data supporting its multi-component cytomegalovirus (CMV) vaccine candidate EVX-V1, which combines AI-discovered antigens with optimized established antigens. The data demonstrates potential to improve control of acute infection, latency, and viral reactivation. EVX-V1 represents a scalable strategy for rational vaccine development across herpesviruses, addressing a significant unmet medical need as no CMV vaccine is currently licensed despite affecting 60-70% of adults in developed countries.